ENSCO will showcase its Assured Positioning, Navigation and Timing (A-PNT) sensing capabilities for edge devices at the Institute of Navigation International Technical Meeting (ITM) virtual meeting, January 25-28, 2021.

Abstract. Governments and financial institutions in several jurisdictions are planning or implementing nonmedical/‘forced’ switches by cutting drug coverage for

FCC ID OWS-NIC514 Application Details

BioStudies – one package for all the data supporting a study

Heparin and Dextrose package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

Big changes are afoot in how Medicare reimburses for Part B drugs, and the reaction to the potential changes has stakeholders scurrying in every direction.

Our list of greenhouse FAQ's cover a wide variety of topics, such as greenhouse costs, understanding our innovative greenhouse technology, winter greenhouse heating & more. Learn more today!

Interchangeability Interchangeability is defined by statute in the United States to mean that the product may be substituted for the reference product without the intervention of the physician who prescribed the reference product. The legal standard for interchangeability is an additional standard beyond demonstration of biosimilarity. According to guidance issued by the FDA in May 2019, in order for a biological product to be deemed interchangeable, the information submitted must be sufficient to show that: The biological product is biosimilar to the reference product and can be expected to produce the same result as the reference product in any given patient For a biologic product that is administered more than once to an individual, the risk in terms of safety or diminished efficacy of alternating or switching between use of the biological product and the reference product is not greater than the risk of using the reference product without such alternation or switch Substitutions In the United States, although Federal law gives the FDA authority to license biologic products as interchangeable, it is the state laws that govern the substitution of biologics and pharmaceuticals.

Guidance Documents Please download the Technical Documents Catalogue that covers the technical guidance and contains an overall view of the standards, recommendations, guidelines, and model courses in force with a […]

Abstract. Identity by descent (IBD) can be reliably detected for long shared DNA segments, which are found in related individuals. However, many studies contain

For patients with chronic illnesses, such as rheumatoid arthritis, multiple sclerosis and cancer, the introduction and development of biologic therapies has been a significant boon to their health and quality of life. Still, the process of finding the correct regimen can be painstaking, and involve months, or even years, of trial and error before a physician and their patient find a therapy that

Europe PMC is an archive of life sciences journal literature.

Large scale genomics projects exploiting high throughput leading technology have produced and continue to produce massive data sets with exponential growing rates. So far, only a small part of this data can be abstracted, managed and processed, giving an incomplete understand...

NCSL’s experts are here to answer your questions and give you unbiased, comprehensive information as soon as you need it on issues facing state legislatures. We answer more than 20,000 requests for information a year.

DuckDuckGo. Privacy, Simplified.

Disclaimer : IALA strives to make the information on this website as accurate as possible but expressly disclaims liability for its content and its use. In case of doubt or […]

Jeffrey D. Janus is Chief Executive Officer of ESI BIO. Mr. Janus previously served as the CEO and founder of Lifeline Cell Technology, LLC,...